Janssen v. Qilu Pharma: ANDA blocked until 2031 on Invega Sustenna patent
Janssen Pharmaceuticals secured final judgment against Qilu Pharmaceutical and Qilu Pharma, Inc. in the District of New Jersey, confirming infringement and validity of US9439906 covering Invega Sustenna (paliperidone palmitate). Qilu’s ANDA No. 217889 is enjoined from market entry until at least January 26, 2031 — a 513-day case resolved through res judicata from two prior Janssen victories.
Res judicata forecloses Qilu’s generic Invega Sustenna challenge
Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica N.V. filed suit on June 18, 2024 in the U.S. District Court for the District of New Jersey against Qilu Pharmaceutical Co., Ltd. and Qilu Pharma, Inc., asserting that Qilu’s ANDA No. 217889 — a generic application for paliperidone palmitate injectable suspension — would infringe US Patent No. 9,439,906. Invega Sustenna is a long-acting injectable antipsychotic and a commercially significant product in Janssen’s CNS portfolio.
The case closed on November 13, 2025, 513 days after filing, with a final judgment entirely in Janssen’s favor. The court’s resolution turned on a January 30, 2025 stipulation (Dkt. 31) binding both parties to the prior judgments and factual findings in the Teva Action (2:18-cv-00734) and the Mylan Action (2:19-cv-16484) — two prior D.N.J. proceedings in which Janssen had already established the infringement and validity of the 906 Patent. Those findings were applied against Qilu as res judicata, foreclosing any independent merits adjudication in this case.
The 513-day resolution is notably swift for ANDA patent litigation, likely reflecting Qilu’s limited ability to relitigate issues already decided in Teva and Mylan. The parties’ stipulation effectively converted a potentially lengthy trial into a consent-to-judgment proceeding. What the public record does not reveal is whether any licensing negotiation or commercial agreement accompanied the stipulation, or what Qilu’s timeline for an alternative product strategy may be. The effective injunction date of January 26, 2031 preserves Janssen’s exclusivity for the remaining patent term.
Filing to Judgment on the merits for Plaintiff in 513 days
513 days — resolved faster than average ANDA patent trial through res judicata binding
Final judgment for Janssen: what the ruling means for both parties
Res judicata bound Qilu to prior Teva and Mylan judgments
Under the January 30, 2025 stipulation, Qilu agreed to be bound by all findings and the final judgments in the Teva Action and Mylan Action as if it had fully participated in those proceedings. This res judicata mechanism allowed the court to enter final judgment without re-litigating infringement or validity — a streamlined procedural path that strongly favoured Janssen and foreclosed Qilu’s independent defences.
Res judicata via stipulationJanssen’s exclusivity on Invega Sustenna preserved through January 2031
The judgment confirms US9439906’s validity and enforceability and imposes a statutory bar under 35 U.S.C. § 271(e)(4)(A) on Qilu’s ANDA effective date until patent expiry. A concurrent injunction under § 271(e)(4)(B) prohibits Qilu from manufacturing, selling, or importing the ANDA product in the U.S. until at least January 26, 2031. Regulatory exclusivities held by Janssen are expressly preserved, potentially extending market protection beyond the patent term.
Exclusivity preserved to Jan 2031Qilu’s generic entry enjoined; ANDA No. 217889 commercially blocked
Qilu and all affiliated entities are enjoined from any commercial activity relating to ANDA No. 217889 in the United States until at least January 26, 2031. By stipulating to the Teva and Mylan findings, Qilu relinquished the right to independently contest infringement or validity — a strategic concession that suggests limited prospects for success on the merits. Qilu must also submit a copy of the final judgment to the FDA within 14 days, formalising the regulatory block.
Generic entry blocked until 2031Third-party ANDA filers face elevated risk on the 906 Patent
The Teva, Mylan, and now Qilu judgments create a consistent body of D.N.J. precedent confirming the validity and infringement of US9439906. Any further ANDA filer challenging this patent faces a heavily precedented judicial record. The paliperidone palmitate long-acting injectable market remains protected for Janssen through at least 2031, and competing generic manufacturers should treat the 906 Patent’s claims as presenting a high litigation risk through the remaining patent term.
High barrier for future ANDA challengersFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Janssen Pharmaceuticals, Inc. | Company | Pharmaceutical patent holder — holder of US9439906 covering Invega Sustenna (paliperidone palmitate)Search in Eureka ↗ |
| Co-Plaintiff | Janssen Pharmaceutica, N.V. | Individual | Search in Eureka ↗ |
| Defendant | Qilu Pharmaceutical Co., Ltd. | Company | Chinese generic pharmaceutical manufacturer and its U.S. affiliate; filed ANDA No. 217889 for paliperidone palmitate injectable suspensionSearch in Eureka ↗ |
| Co-Defendant | Qilu Pharma, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Keith J. Miller | Attorney | Counsel for Janssen Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Robinson Miller LLC | Law Firm | Representing Janssen Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Ian Scott | Attorney | Counsel for Qilu Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Defendant law firm | Taft, Stettinius & Hollister LLP | Law Firm | Representing Qilu Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The final judgment’s reliance on res judicata from the Teva and Mylan actions is analytically significant: the court did not conduct independent merits analysis but instead gave binding effect to a stipulated consent order. The injunction language tracks § 271(e)(4)(B) precisely, covering all affiliates and agents, which limits Qilu’s ability to route commercial activity through related entities. The express preservation of regulatory exclusivities in paragraph 6 is a forward-looking protective clause that could extend Janssen’s practical market exclusivity beyond the January 26, 2031 patent expiry date. The FDA submission requirement within 14 days operationalises the judgment at the regulatory level.
US9439906 — Paliperidone palmitate injectable antipsychotic formulation
US Patent No. 9,439,906 (application no. US12/337,144) protects formulations and methods relating to paliperidone palmitate, the active moiety in Invega Sustenna — a once-monthly long-acting injectable antipsychotic approved for schizophrenia and schizoaffective disorder. The patent’s claims cover the specific pharmaceutical composition enabling sustained-release injectable delivery, a technically demanding formulation challenge that underpins Invega Sustenna’s clinical differentiation from oral antipsychotics. The patent is currently set to expire on January 26, 2031.
US9439906 has now withstood validity and infringement challenges from at least three separate generic pharmaceutical companies — Teva, Mylan, and Qilu — all in the District of New Jersey. This track record of successful enforcement significantly strengthens the patent’s deterrent value for any further ANDA challenger. For companies operating in the long-acting injectable CNS space, the 906 Patent represents a durable barrier to generic market entry, and its claims should be carefully evaluated by any formulator developing paliperidone palmitate depot products intended for the U.S. market.
Should you run an FTO against US9439906 before developing paliperidone palmitate injectables?
Any R&D team or generic manufacturer developing a paliperidone palmitate injectable suspension for the U.S. market must conduct a thorough freedom-to-operate analysis against US9439906 before advancing formulation work. Given three consecutive enforcement wins in the District of New Jersey, the 906 Patent’s claims have been judicially validated at a high confidence level. Even ANDA filers with differentiated formulation approaches carry meaningful litigation risk given the breadth of the claims as interpreted in the Teva and Mylan proceedings.
PatSnap Eureka’s FTO Search Agent can map your candidate formulation’s features against the claim scope of US9439906, surface related family members and continuation applications, and flag prosecution history estoppel that may limit or expand the claims’ reach. Eureka’s landscape view also identifies the existing prior art used in the Teva and Mylan proceedings, helping your team assess whether any residual invalidity arguments remain viable — or whether licensing is the commercially rational path.
Run a freedom-to-operate analysis on US9439906B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA pharmaceutical patent cases in the District of New Jersey
Cases involving Hatch-Waxman ANDA challenges to branded injectable CNS formulation patents litigated in D.N.J., including related Janssen Invega Sustenna proceedings.
What this case signals for the pharmaceutical ANDA IP landscape
Three consecutive Janssen wins on US9439906 create a durable precedent wall — generic challengers face compounding legal risk.
Res judicata as a consent judgment tool is increasingly common in ANDA disputes
When a patent holder has won prior ANDA trials on the same patent, subsequent defendants often face a binary choice: litigate an uphill battle or stipulate to prior findings. Qilu’s decision to accept res judicata binding suggests its ANDA position offered limited differentiation from the Teva and Mylan arguments. IP teams monitoring competitive ANDA filings should track prior judgments on the same patent as leading indicators of case trajectory.
Injunctions under § 271(e)(4)(B) reinforce patent term value in CNS injectables
The court’s injunction under 35 U.S.C. § 271(e)(4)(B) explicitly extends to Qilu’s affiliates, successors, and agents — a broad scope that limits workarounds. For branded CNS injectable manufacturers, securing and enforcing long-acting injectable formulation patents through to expiry is demonstrably achievable in the District of New Jersey, which has an established and patent-holder-friendly ANDA litigation record.
Janssen v Qilu — key questions answered
Final judgment was entered in favor of Janssen on November 13, 2025. The court held that US9439906 is valid and infringed by Qilu’s ANDA No. 217889, enjoining Qilu from commercial activities relating to its generic paliperidone palmitate product until at least January 26, 2031.
On January 30, 2025, the parties entered a stipulation binding Qilu to the findings and final judgments in the prior Teva Action (2:18-cv-00734) and Mylan Action (2:19-cv-16484), in which infringement and validity of US9439906 had already been established. By stipulating to this binding effect, Qilu agreed that those prior adjudications applied as res judicata in this case.
The injunction prohibits Qilu and all its affiliates, successors, partners, officers, agents, and employees from commercially manufacturing, using, offering to sell, selling within, or importing into the United States the products that are the subject of ANDA No. 217889 until no earlier than the expiration of US9439906 on January 26, 2031.
US9439906 protects pharmaceutical formulations of paliperidone palmitate, the active ingredient in Janssen’s Invega Sustenna — a once-monthly long-acting injectable antipsychotic. The patent covers the composition and methods enabling sustained-release injectable delivery and is currently set to expire January 26, 2031.
The final judgment expressly states it has no effect on any regulatory exclusivities to which Janssen may become entitled after entry. This means FDA-granted exclusivities — such as pediatric exclusivity or new formulation exclusivity — could delay approval of Qilu’s ANDA beyond the January 26, 2031 patent expiry, though no specific exclusivity is confirmed in the public record of this case.
PatSnap Eureka searches patents and litigation data to answer instantly.